CNS Pharmaceuticals, Inc. (CNSP) Total Return Calculator with Dividends Reinvested

CNS Pharmaceuticals, Inc.

Popular:

The total return for CNS Pharmaceuticals, Inc. (CNSP) stock is -54.18% over the past 12 months. So far it's down 21.32% this year. The 5-year total return is -100.00%, meaning $10,000 invested in CNSP stock 5 years ago would be worth $0 today. Total return includes price appreciation plus reinvesting any dividends paid out.

If you invested $10,000 in CNSP 1 year ago, it would be worth $4,020 today — you'd have lost $5,980.

With Dividends Reinvested$4,020-59.80%

Price Only (No DRIP)$4,020-59.80%

Period2025-06-30 → 2026-06-26

Price

Total Return (DRIP)

S&P 500

If You Invested $10,000 in CNSP

1Y$4,582-$5,418 (-54.2%)-54.2% CAGR

3Y$1-$9,999 (-100.0%)-96.0% CAGR

5Y$0-$10,000 (-100.0%)-91.7% CAGR

10Y$0-$10,000 (-100.0%)-71.1% CAGR

15Y$0-$10,000 (-100.0%)-56.3% CAGR

20Y$0-$10,000 (-100.0%)-46.3% CAGR

30Y$0-$10,000 (-100.0%)-33.9% CAGR

CNS Pharmaceuticals, Inc. did not pay dividends during this period. Total return = price return.

Loading CNSP total return...

As of 2026-06-28

Performance Summary

Best Year+0.00%2019

Worst Year-99.80%2024

Max Drawdown-81.12%2025-07-09 → 2026-04-09

Period	Total Return	CAGR	Price Only	Div. Contrib.	$10K →
YTD	-21.32%	—	-24.91%	+3.58 pp	$7,868
1Y	-54.18%	-54.18%	-60.36%	+6.18 pp	$4,582
3Y	-99.99%	-95.98%	-99.99%	—	$1
5Y	-100.00%	-91.67%	-100.00%	—	$0
10Y	-100.00%	-71.15%	-100.00%	—	$0
15Y	-100.00%	-56.33%	-100.00%	—	$0
20Y	-100.00%	-46.28%	-100.00%	—	$0
30Y	-100.00%	-33.92%	-100.00%	—	$0

Annual Returns

Year	Total Return	Price Return	Div.	S&P 500	vs S&P
2026YTD	-41.32%	-41.32%	—	+0.41%	-41.7pp
2025	-92.52%	-92.52%	—	+16.64%	-109.2pp
2024	-99.80%	-99.80%	—	+24.00%	-123.8pp
2023	-52.26%	-52.26%	—	+24.81%	-77.1pp
2022	-89.64%	-89.64%	—	-19.95%	-69.7pp

CNSP underperformed the S&P 500 by 75.02pp over the past year (-54.18% vs +20.84%).

Loading summary...

CNSP Peers' Total Return

Accurate peer set · 10 comparable names

Name	Mkt Cap	30D Rtn	YTD Total Rtn	1Y Total Rtn	Div Contrib	3Y Total Rtn	5Y Total Rtn	10Y Total Rtn
CNSPCNS Pharmaceuticals, Inc.	$3M	-25.0%	-21.3%	-54.2%	—	-100.0%	-100.0%	-100.0%
NKTRNektar Therapeutics	$1.2B	-2.9%	+49.5%	+165.4%	—	+621.1%	-74.6%	-69.9%
SNDXSyndax Pharmaceuticals, Inc.	$1.9B	+7.1%	-6.2%	+116.7%	—	-4.9%	+10.1%	+87.4%
KALAKALA BIO, Inc.	$55M	+16.1%	-90.3%	-98.5%	—	-99.6%	-100.0%	-100.0%
ALDXAldeyra Therapeutics, Inc.	$110M	+2.8%	-59.3%	-43.3%	—	-74.7%	-83.1%	-64.2%
AGIOAgios Pharmaceuticals, Inc.	$2.3B	+33.8%	+33.5%	+8.6%	—	+32.1%	-35.9%	-18.0%
NVCRNovoCure Limited	$1.8B	-15.5%	+12.2%	-13.4%	—	-64.5%	-93.4%	+38.7%
IMVTImmunovant, Inc.	$8.0B	+14.8%	+47.5%	+138.9%	—	+98.5%	+247.5%	+284.1%
PRAXPraxis Precision Medicines, Inc.	$9.5B	-6.5%	+7.9%	+602.8%	—	+1824.9%	+5.4%	-25.9%
ACADACADIA Pharmaceuticals Inc.	$4.3B	+19.1%	-10.7%	+4.2%	—	-2.1%	-6.6%	-25.7%
CRLCharles River Laboratories International, Inc.	$10.4B	+37.7%	-0.2%	+36.2%	—	-2.0%	-44.9%	+151.5%

Compare:CNSP vs NKTR CNSP vs SNDX CNSP vs KALA CNSP vs NKTR vs SNDX

About CNSP Dividend Returns

CNS Pharmaceuticals, Inc. (CNSP) does not currently pay dividends. Many growth-focused companies reinvest profits back into the business rather than distributing them as dividends.

How We Calculate Total Return

Our total return calculator simulates dividend reinvestment (DRIP) by assuming each dividend payment is used to purchase additional shares at the closing price on the ex-dividend date. This methodology provides an accurate representation of how a dividend reinvestment plan would perform.

Frequently Asked Questions

Q1What is the total return of CNSP over the past year?

CNS Pharmaceuticals, Inc. (CNSP) delivered a return of -54.18% over the past year. Since CNSP does not currently pay dividends, the total return equals the price-only return.

Q2How much would $10,000 invested in CNSP be worth today?

A $10,000 investment in CNS Pharmaceuticals, Inc. one year ago would be worth $4,582 today, representing a loss of $5,418.

Q3Does CNSP pay dividends?

CNS Pharmaceuticals, Inc. (CNSP) does not currently pay dividends. Many growth-focused companies reinvest profits back into the business rather than distributing them as dividends. For CNSP, the total return equals the price-only return.

Q4Did CNSP beat the S&P 500?

No, CNS Pharmaceuticals, Inc. (CNSP) underperformed the S&P 500 by 75.02 percentage points over the past year. CNSP delivered a total return of -54.18%, compared to the S&P 500's 20.84%. This means a passive S&P 500 index fund outperformed CNSP by 75.02pp during this period.

Q5What is CNSP's worst drawdown?

CNS Pharmaceuticals, Inc. (CNSP) experienced a maximum drawdown of -81.12% over the past year, declining from its peak on 2025-07-09 to its trough on 2026-04-09. The stock has not yet fully recovered to its prior peak. Maximum drawdown measures the worst peak-to-trough decline and is an important risk metric for investors.

Q6What is CNSP's long-term total return over 10, 20, or 30 years?

Here are CNS Pharmaceuticals, Inc. (CNSP)'s long-term returns with dividends reinvested. Over 10 years, the total return is -100.0% (-71.1% CAGR) — $10,000 would have grown to $0. Over 20 years: -100.0% total return (-46.3% CAGR) — $10,000 → $0. Over 30 years: -100.0% total return (-33.9% CAGR) — $10,000 → $0. Long-term investors benefit from compounding: dividends buy additional shares, which generate their own dividends, creating an exponential growth effect.

Q7What was CNSP's best and worst year?

CNS Pharmaceuticals, Inc.'s best calendar year was 2019 with a total return of 0.0%. Its worst year was 2024 with a total return of -99.8%. This range shows the volatility investors should expect — the difference between the best and worst year is 99.8 percentage points.

How much would $100/month in CNSP be worth today?

Dollar cost averaging calculator · DCA vs lump sum · see how regular investing compounds

Run the Numbers →